Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Noh, Ji Heon ^a   Jung, Kwang Hwa ^a   Kim, Jeong Kyu ^a   Eun, Jung Woo ^a   Bae, Hyun Jin ^a   Xie, Hong Jian ^a   Chang, Young Gyoon ^a   Kim, Min Gyu ^a   Park, Won Sang ^a   Lee, Jung Young ^a   Nam, Suk Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE DEACETYLASE 2; MYC PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR SP1; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEACETYLASE INHIBITOR; MITOGENIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; ANIMAL; CELL TRANSFORMATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PROTEIN BINDING; WNT SIGNALING PATHWAY;

ANIMALS; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME ACTIVATION; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; MICE; MITOGENS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; S PHASE; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; WNT SIGNALING PATHWAY;

EID: 81755176121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028103     Document Type: Article

References (30)

1. Glozak MA, Seto E, (2007) Histone deacetylases and cancer. Oncogene 26: 5420-5432.
2. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C, (2007) HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17: 195-211.
3. Witt O, Deubzer HE, Milde T, Oehme I, (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21.
4. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202.
5. Yang XJ, Seto E, (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26: 5310-5318.
6. Batty N, Malouf GG, Issa JP, (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280: 192-200.
7. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, et al. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463.
8. Noh JH, Eun JW, Ryu SY, Jeong KW, Kim JK, et al. (2006) Increased Expression of Histone Deacetylase 2 is Found in Human Hepatocellular Carcinoma. Molecular & Cellular Toxicology 2: 166-169.
9. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, et al. (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113: 264-268.
10. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, et al. (2005) Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42: 809-818.
11. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, et al. (2005) Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42: 210-217.
12. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, et al. (2007) Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46: 1119-1130.
13. Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, et al. (2006) HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43: 425-434.
14. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, et al. (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773.
15. Grana X, Reddy EP, (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219.
16. Huang W, Tan D, Wang X, Han S, Tan J, et al. (2006) Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1. Biochem Biophys Res Commun 339: 165-171.
17. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA, (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 101: 1241-1246.
18. Weichert W, (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280: 168-176.
19. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, et al. (2006) Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5: 2203-2210.
20. Huang BH, Laban M, Leung CH, Lee L, Lee CK, et al. (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404.
21. Kaler P, Sasazuki T, Shirasawa S, Augenlicht L, Klampfer L, (2008) HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Exp Cell Res 314: 1507-1518.
22. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, et al. (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98: 604-610.
23. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, et al. (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391: 597-601.
24. Luo J, Su F, Chen D, Shiloh A, Gu W, (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
25. Yarden RI, Brody LC, (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A 96: 4983-4988.
26. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, et al. (1997) Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89: 349-356.
27. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, et al. (1997) Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150.
28. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, et al. (1997) Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272: 22199-22206.
29. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C, (2006) Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319.
30. Niyazi M, Niyazi I, Belka C, (2007) Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol 2: 4.